Shares of ImmuPharma plc (LON:IMM – Get Free Report) shot up 12.8% on Monday . The company traded as high as GBX 4.95 ($0.06) and last traded at GBX 4.44 ($0.06). 11,150,036 shares were traded during trading, a decline of 42% from the average session volume of 19,209,219 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Trading Up 12.8 %
The stock has a market capitalization of £18.49 million, a PE ratio of -444.00 and a beta of 1.53. The business’s 50 day moving average is GBX 1.75 and its 200 day moving average is GBX 1.73.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- 3 Dividend Kings To Consider
- MP Materials: Rare Earth Elements Powering the EV Boom
- What Investors Need to Know to Beat the Market
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- How to Invest in the Best Canadian Stocks
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
